Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Paladino, J. A.
Right arrow Articles by Callen, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paladino, J. A.
Right arrow Articles by Callen, W. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 43-47
© 2003 The British Society for Antimicrobial Chemotherapy

Supplement

Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters

Joseph A. Paladino1,*,2 and Wendy A. Callen1

1 CPL Associates LLC, 3980 Sheridan Drive, Amherst, NY 14226; 2 State University of New York at Buffalo, Buffalo, NY, USA

Abstract

The expanding class of fluoroquinolone antibiotics comprises numerous agents that differ in pharmacokinetic (PK) characteristics as well as pharmacodynamic (PD) activity. Although generally considered as potent compounds as a class, their individual in vitro activities, as measured by minimum inhibitory concentrations (MIC) demonstrate considerable variability. Objective pharmacological measures such as Cmax/MIC and AUC24/MIC, also known as area under the inhibitory curve (AUIC), have been shown to predict bacteriological eradication, clinical efficacy, emergence of resistant substrains and economic results. These PK/PD measures describe in vivo potency and can provide scientific guidance to clinicians when deciding which agent to use at the bedside of individual patients, and to healthcare administrators when deciding the formulary status for individual agents.

Footnotes

* Corresponding author. Tel: +1-716-839-4931; Fax: +1-716-839-5138; E-mail: paladino{at}cplassociates.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. M. Haritova, N. V. Rusenova, P. R. Parvanov, L. D. Lashev, and J. Fink-Gremmels
Integration of Pharmacokinetic and Pharmacodynamic Indices of Marbofloxacin in Turkeys
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3779 - 3785.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.